Insights from the CAMP-1 and CAMP-2 studies on cantharidin solution (0.7%) in molluscum contagiosum: James Del Rosso

Dr. James Del Rosso (JDR Dermatology Research, Las Vegas, Nevada, USA, and President-Elect American Acne & Rosacea Society) discusses the efficacy and safety results from the CAMP-1 and CAMP-2 studies, highlighting their role in supporting the recent FDA approval cantharidin solution (0.7%) for treatment of molluscum contagiosum. He also examines who benefits most from the cantharidin topical solution and outlines its side effects. Additionally, Dr. Del Rosso explores the impact of FDA approval on clinical practice and the increased availability of this treatment.

Watch the expert perspective interview with Dr James Del Rosso on cantharidin solution (0.7%) drug-device combination and its use in molluscum contagiosum

Questions:

1. Could you give us a brief overview of the efficacy and safety findings from CAMP-1 and CAMP-2 and how this data supported FDA approval?
2. Who is likely to benefit most from cantharidin topical solution and what side effects are associated with use?
3. What will be the impact of FDA approval on clinical practice and how will this increase the availability of treatment?

Disclosures: James Del Rosso is a consultant and speaker for Verrica pharmaceuticals.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.